Blueprint Medicines Corporation
BPMC Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
BPMC Income Statement
BPMC Balance Sheet
BPMC Cash Flow
Recent trades of BPMC by members of U.S. Congress
BPMC Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
BPMC Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
BPMC Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by BPMC's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Aug. 13, 2024
-
Patent Title: Map4k1 inhibitors Jul. 23, 2024
-
Patent Title: Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Jun. 04, 2024
-
Patent Title: Cdk2 inhibitors Apr. 30, 2024
-
Patent Title: Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Apr. 23, 2024
-
Patent Title: Cdk2 inhibitors Mar. 19, 2024
-
Patent Title: Ret inhibitor for use in treating cancer having a ret alteration Jan. 16, 2024
-
Patent Title: Compositions useful for treating disorders related to kit Nov. 28, 2023
-
Patent Title: Egfr inhibitors Aug. 08, 2023
-
Patent Title: Inhibitors of activin receptor-like kinase Apr. 25, 2023
-
Patent Title: Map4k1 inhibitors Dec. 27, 2022
-
Patent Title: Inhibitors of ret Mar. 22, 2022
-
Patent Title: Ret inhibitor for use in treating cancer having a ret alteration Mar. 15, 2022
-
Patent Title: Prkc fusions Mar. 01, 2022
-
Patent Title: Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase Feb. 01, 2022
-
Patent Title: Compounds and compositions useful for treating disorders related to ntrk Jul. 13, 2021
-
Patent Title: Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to kit and pdgfr Jun. 22, 2021
-
Patent Title: Pik3c2g fusions Dec. 29, 2020
-
Patent Title: Inhibitors of the fibroblast growth factor receptor Dec. 29, 2020
-
Patent Title: Compositions and methods for treating kit- and pdgfra-mediated diseases Nov. 10, 2020
-
Patent Title: Compositions useful for treating disorders related to kit Oct. 20, 2020
-
Patent Title: 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors Sep. 15, 2020
-
Patent Title: Pik3ca fusions Jun. 02, 2020
-
Patent Title: Inhibitors of activin receptor-like kinase Jun. 02, 2020
-
Patent Title: Inhibitors of ret Mar. 10, 2020
-
Patent Title: Ntrk2 fusions Sep. 10, 2019
-
Patent Title: Raf1 fusions Aug. 13, 2019
-
Patent Title: Fgr fusions Aug. 06, 2019
-
Patent Title: Prkc fusions Aug. 06, 2019
-
Patent Title: Tert fusions Aug. 06, 2019
-
Patent Title: Compounds and compositions useful for treating disorders related to ntrk Aug. 06, 2019
-
Patent Title: Method for detection of a tecr:pkn1 or an anxa4:pkn1 gene fusion Apr. 02, 2019
-
Patent Title: Inhibitors of activin receptor-like kinase Mar. 19, 2019
-
Patent Title: Compounds useful for treating disorders related to ret Mar. 12, 2019
-
Patent Title: Inhibitors of the fibroblast growth factor receptor Mar. 05, 2019
-
Patent Title: 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors Feb. 12, 2019
-
Patent Title: Inhibitors of the fibroblast growth factor receptor Feb. 05, 2019
-
Patent Title: Inhibitors of ret Jan. 22, 2019
-
Patent Title: Compounds useful for treating disorders related to ret Jul. 31, 2018
-
Patent Title: Inhibitors of ret Jul. 24, 2018
-
Patent Title: Compounds and compositions useful for treating disorders related to ntrk Jul. 10, 2018
-
Patent Title: Compositions useful for treating disorders related to kit and pdgfr Jun. 19, 2018
-
Patent Title: Inhibitors of the fibroblast growth factor receptor Jun. 19, 2018
-
Patent Title: Compositions useful for treating disorders related to kit Jun. 12, 2018
-
Patent Title: Compositions useful for treating disorders related to kit Jun. 12, 2018
-
Patent Title: Compositions useful for treating disorders related to kit Apr. 17, 2018
-
Patent Title: Compositions useful for treating disorders related to kit Feb. 06, 2018
-
Patent Title: Inhibitors of the fibroblast growth factor receptor Jul. 04, 2017
-
Patent Title: Compositions useful for treating disorders related to kit Jun. 27, 2017
-
Patent Title: Compositions useful for treating disorders related to kit Nov. 22, 2016
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of BPMC in WallStreetBets Daily Discussion
BPMC News
Recent insights relating to BPMC
CNBC Recommendations
Recent picks made for BPMC stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in BPMC
BPMC Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view BPMC Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More